Exploring the role of sclerostin in bone disease related to mastocytosis
Role of Sclerostin in Mastocytosis Bone Disease
This study is trying to see how levels of a protein called sclerostin affect bone health in adults with mastocytosis compared to healthy volunteers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Lublin Academic / other |
| Locations | 1 site (Lublin, Lublin Voivodeship) |
| Trial ID | NCT06440148 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between circulating sclerostin levels and bone lesions in patients diagnosed with mastocytosis, a rare disorder characterized by the accumulation of mast cells. The research aims to understand how sclerostin, a protein involved in bone metabolism, may contribute to bone changes in patients with different clinical variants of mastocytosis. Participants include adults with various forms of mastocytosis and healthy volunteers, with assessments involving blood tests and low-dose CT scans to evaluate bone health. The study employs advanced techniques such as Real-Time PCR and ELISA to analyze sclerostin levels and gene expression.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with a confirmed diagnosis of mastocytosis according to WHO criteria.
Not a fit: Patients with a history of organ transplant, those unable to provide informed consent, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of bone disease in mastocytosis and lead to improved management strategies for affected patients.
How similar studies have performed: While the specific relationship between sclerostin and mastocytosis has not been extensively studied, research on sclerostin's role in bone metabolism has shown promise in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * Mastocytosis defined according to WHO criteria * Known KIT mutation status Exclusion Criteria: * History of organ transplant * Inability to give informed consent * Pregnancy, Breastfeeding * Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection
Where this trial is running
Lublin, Lublin Voivodeship
- Department of Hematooncology and Bone Marrow Transplantation — Lublin, Lublin Voivodeship, Poland (Recruiting)
Study contacts
- Principal investigator: Aneta A Szudy-Szczyrek, MD., PhD. — Medical University of Lublin
- Study coordinator: Aneta Szudy-Szczyrek, MD., PhD.
- Email: aneta.szudy-szczyrek@umlub.pl
- Phone: +48815345468
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.